

Application No.: Not Yet Assigned

10/501699  
DT04 Rec'd PCT/PTO 1 6 JUL 2004  
Docket No.: LYMF-P01-004

**REMARKS**

The specification was amended to add the priority claim paragraph and to incorporate the abstract in accordance with U.S. practice. Applicants assert that no new matter has been added by these amendments.

**CONCLUSION**

Please charge any fees due or credit any overpayment to our Deposit Account No. 18-1945, under Order No. LYMF-P01-004 from which the undersigned is authorized to draw.

Dated: June 16, 2004

Respectfully submitted,

By DSR

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

Application No.: Not Yet Assigned


Docket No.: LYMF-P01-004

**ABSTRACT**

**COMPOUNDS FOR MODULATING CELL PROLIFERATION**

The following compounds of formulae (I) and (III) which may be useful in treating a variety of cell proliferative disorders are disclosed: Formula (I), (II), wherein  $R^1$ ,  $R^2$  and  $R^3$  are each independently selected from H, OH,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $NH_2$ ,  $NH-C_{1-6}$ alkyl,  $N(C_{1-6}$  alkyl), SH,  $S-C_{1-6}$  alkyl,  $NO_2$ ,  $CF_3$ ,  $OCF_3$  and halo;  $R^4$  is unsubstituted Ar, or Ar substituted with 1-4 substituents, independently selected from  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy and halo; X is selected from  $(CH_2CH_2O)_n$  and  $(CH_2)_n$ , and  $n=1-4$ .

(I)



(III)

